Literature DB >> 2834842

In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.

J M Dickinson1, D A Mitchison.   

Abstract

Comparisons were made of the in vitro activity of rifampicin, and the rifamycin derivatives, rifapentine, rifabutin, CGP 29861, CGP 7040 and CGP 27557, against rifampicin-sensitive and rifampicin-resistant strains of Mycobacterium tuberculosis and against the Mycobacterium avium/intracellulare/scrofulaceum (MAIS) complex. The new rifamycins had MICs four to eight times lower than those of rifampicin against sensitive M. tuberculosis strains. Of the 35 rifampicin-resistant strains of M. tuberculosis, 31% were sensitive to rifabutin but only 3-11% to the other rifamycins. The proportions of the MAIS strains found to be sensitive were 35% for rifampicin, 50-60% for CGP 27557, rifapentine and rifabutin and 85-92% for CGP 29861 and CGP 7040.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2834842     DOI: 10.1016/0041-3879(87)90053-5

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  22 in total

1.  Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.

Authors:  A C Keung; R C Owens; M G Eller; S J Weir; D P Nicolau; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

Review 3.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 4.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

5.  In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Whole genome sequence of the rifamycin B-producing strain Amycolatopsis mediterranei S699.

Authors:  Mansi Verma; Jaspreet Kaur; Mukesh Kumar; Kirti Kumari; Anjali Saxena; Shailly Anand; Aeshna Nigam; Vydianathan Ravi; Saurabh Raghuvanshi; Paramjit Khurana; Akhilesh K Tyagi; Jitendra P Khurana; Rup Lal
Journal:  J Bacteriol       Date:  2011-10       Impact factor: 3.490

7.  Single-dose pharmacokinetics of rifapentine in elderly men.

Authors:  A C Keung; M G Eller; S J Weir
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

8.  Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex.

Authors:  S P Klemens; M A Grossi; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 10.  Rifapentine.

Authors:  B Jarvis; H M Lamb
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.